https://www.prnewswire.com/news-releases/halozyme-to-host-fourth-quarter-and-full-year-2018-financial-results-webcast-and-conference-call-300792018.html
Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its...
https://www.benzinga.com/insights/analyst-ratings/25/02/43460171/demystifying-halozyme-therapeutics-insights-from-8-analyst-reviews
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews - Halozyme Therapeutics...
halozyme therapeuticsdemystifyinginsightsanalystreviews
https://www.benzinga.com/insights/short-sellers/24/12/42445232/halo-analyzing-halozyme-therapeuticss-short-interest
(HALO) - Analyzing Halozyme Therapeutics's Short Interest - Halozyme Therapeutics (NASDAQ:HALO) -...
halozyme therapeuticsshort interestanalyzingnasdaq
https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios
Halozyme Therapeutics, Inc. Common Stock (HALO) Price/Earnings & PEG Ratios | Nasdaq
Get updated information on Halozyme Therapeutics, Inc. Common Stock (HALO) Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluations with Nasdaq.
halozyme therapeuticscommon stockinc
https://ir.halozyme.com/overview/default.aspx
Halozyme Therapeutics, Inc. - Investor Relations
halozyme therapeuticsincinvestorrelations
https://pharma.economictimes.indiatimes.com/news/pharma-industry/halozyme-makes-2-billion-euro-buyout-offer-for-drug-developer-evotec/115323588
Halozyme Buyout Evotec: Halozyme makes 2 billion euro buyout offer for drug developer Evotec,...
Halozyme Buyout Evotec: Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5 per cent to Evotec's...
halozymebuyoutevotecmakes
https://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-upcoming-healthcare-conference-300604620.html
Halozyme Therapeutics To Present At Upcoming Healthcare Conference
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting...
halozyme therapeuticspresentupcominghealthcareconference
https://pro.thestreet.com/thefly-newsbreaks/halo-halozyme-price-target-raised-by-at-wells-fargo-heres-why
Halozyme price target raised by $10 at Wells Fargo, here's why | TheStreet Pro
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's...
https://www.nasdaq.com/market-activity/stocks/halo/short-interest
Halozyme Therapeutics, Inc. Common Stock (HALO) Short Interest | Nasdaq
Find the latest on short interest, settlement dates, average share volume, and days to cover for Halozyme Therapeutics, Inc. Common Stock (HALO) at Nasdaq.com.
halozyme therapeuticscommon stockshort interestincnasdaq
https://halozyme.com/
Reinventing the patient experience. | Halozyme
the patient experiencereinventinghalozyme